ClinicalTrials.gg
CompletedNCT07769645LEIAUpdated Aug 18, 2026

Length of Stay in Emergency Department: Impact of Anticipated Blood Sampling (LEIA)

An observational study in Length of Stay, Blood Sampling and Crowding, sponsored by Centre Hospitalier de Roubaix. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Centre Hospitalier de Roubaix · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
28,421
Ages
18 Years and older
Sex
All
01

Study summary

The number of emergency department visits is constantly increasing France. Over the past three decades, the figure has risen from 10 million to more than 20 million visits per year. This is often attributed to a shortage of available primary care physicians and patients' inability to obtain timely appointments, whether for general practice or specialist consultations. It should also be noted that following the COVID-19 pandemic, the resurgence in emergency department attendance has further strained services. An aging population is associated with more advanced chronic conditions that are prone to decompensation, as well as more frequent acute illnesses resulting from increasing age-related frailty.

In France, the healthcare system encompasses 719 emergency departments, predominantly located in public healthcare institutions. Emergency departments manage medical, psychiatric, surgical, and traumatological emergencies in both children and adults. The current context is further characterized by a reduction in the number of available downstream inpatient beds nationwide, with an average decrease of approximately 1,390 beds per year between 2014 and 2023.

These various factors contribute to high emergency department utilization rates and occupancy levels. Emergency department length of stay has been shown to impact in-hospital mortality, particularly among patients aged 75 and over, and also negatively affects patient experience as well as the mental health of healthcare workers. One of the key challenges is to identify ways of reducing emergency department length of stay in order to improve patient flow and thereby decrease occupancy rates. Better control of these factors may also reduce morbidity and mortality associated with overcrowded emergency departments, as well as mean inpatient length of stay.

Emergency department length of stay depends on multiple factors, including waiting time before triage and placement, time to medical advice, time to blood sampling and imaging results when ordered, and time to specialist consultation when required. Additional delays may also arise from waiting for an inpatient bed to become available. All of these steps affect length of stay but are necessary to establish an accurate diagnosis and determine the appropriate disposition for each patient. Triage, using the FRENCH scale applied to patients in this study, may itself have an impact when performed rigorously, although blood tests have been shown to outperform algorithm-based triage in predicting short-term mortality. However, when unnecessary tests are performed through systematic blood sampling, emergency department length of stay is prolonged.

In the study by Strada, which evaluated anticipated blood sampling for abdominal pain, chest pain, and non-traumatic bleeding, a benefit was identified only for chest pain. Another study, conducted on a small sample, found no influence of blood testing on emergency department length of stay.

A further study evaluated point-of-care testing in the emergency department, which significantly reduced the time between test ordering and result availability, but demonstrated no impact on emergency department length of stay.

At the emergency department of the Centre Hospitalier de Roubaix, an increase in admissions and time to first medical contact has been observed, and several protocols have already been implemented to improve length of stay. Since November 2024, a high-flow procedure has been introduced enabling anticipated blood sampling prior to the first medical contact.

The primary objective of the study is to evaluate the impact of anticipated blood sampling on emergency department length of stay. Secondary objectives include the impact of anticipated blood sampling on length of stay according to patient disposition, and its impact on time to first medical contact.

02

Conditions studied

  • Length of Stay
  • Blood Sampling
  • Crowding

Keywords

  • Overcrowding
  • Emergency Department
  • Anticipated Blood Sampling
  • propensity score
03

In context

Crowding

88 studies on the registry are indexed under Crowding; 22 are open to participants now.

This study's enrollment of 28,421 is above the median of 664 across 14 observational studies indexed under Crowding.

Browse Crowding studies →

Lead sponsor

Centre Hospitalier de Roubaix is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients admitted in ED between 01/01/2025and 12/31/2025 wha had blood sampling.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years and older
  • Blood sampling realized in ED

Exclusion criteria

Exclusion Criteria:

  • Patients without triage
  • Patients without complaint
  • Patient's refusal
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
28,421 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • No ABS

    Patient who don't have anticipated blood sampling

    Procedure: No Anticipated Blood Sampling

  • ABS

    Patient who have anticipated blood sampling

    Procedure: Anticipated blood sampling

Interventions

  • ProcedureAnticipated blood sampling

    Blood sampling was considered as anticipated if it has been realized a least 103 minutes before medical advice.

  • ProcedureNo Anticipated Blood Sampling

    If blood sampling was realized between 103 minutes before medical advice a medical advice or after.

06

What researchers measure

Primary outcomes

  1. lenght of stay

    Delay between admission and discharge of emergency department

    Time frame: From ED admission to ED discharge, assessed over a 12-month period (January 1 to December 31, 2025)

Secondary outcomes

  1. Time to doctor

    Delay between admissions and first medical advice in ED

    Time frame: From ED admission to ED discharge, assessed over a 12-month period (January 1 to December 31, 2025)

Other outcomes

  1. Anticipated Blood Sampling

    Blood Sampling realized at least 103 minutes before medical advice

    Time frame: From ED admission to ED discharge, assessed over a 12-month period (January 1 to December 31, 2025)

07

Study locations

1 site
  • Centre Hospitalire de Roubaix
    Roubaix, 59100, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Dec 2025, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2026
First posted
Aug 18, 2026
StartActual
Jan 1, 2025
Primary completionActual
Dec 31, 2025
CompletionActual
Apr 4, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07769645
Lead sponsor
Centre Hospitalier de Roubaix
Responsible party
Rémy DIESNIS (Medical Doctor, Head of Research Unit, Centre Hospitalier de Roubaix) — Principal investigator
First posted
Aug 18, 2026
Start date
Jan 1, 2025
Primary completion
Dec 31, 2025
Completion
Apr 4, 2026
Last update
Aug 18, 2026

Study contacts

Rémy Diesnis, MD
principal investigator · Centre Hospirtalier de Roubaix

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion